Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics director Samantha Truex exercised restricted stock units into common shares. On March 28, the vesting and exercise of 3,166 restricted stock units at $0.00 per unit delivered 3,166 shares of common stock, bringing her direct common stock holdings to 6,333 shares.
These units are part of a grant of 9,500 restricted stock units awarded on August 13, 2024, which vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on her continued service.
Avalo Therapeutics director Aaron Kantoff exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a stated price of $0.00 per share.
After the transaction, Kantoff directly held 6,333 shares of common stock. The restricted stock units were part of a 9,500-unit grant awarded on August 13, 2024, scheduled to vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service. No open-market buy or sell was reported in this filing; it reflects a derivative exercise tied to equity compensation.
Avalo Therapeutics director Gilla Kaplan exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a price of $0.00 per share, reflecting a routine compensation-related equity conversion rather than an open-market trade.
Following the transaction, Kaplan directly held 6,333 shares of Avalo Therapeutics common stock and 3,167 restricted stock units. The restricted stock units convert into common stock on a one-for-one basis and were part of a 9,500-unit grant made on August 13, 2024, vesting in three equal annual installments.
Avalo Therapeutics, Inc. Chief Executive Officer Neil Garry Arthur exercised restricted stock units that converted into common stock and had shares withheld for taxes. He exercised 64,866 restricted stock units into 64,866 shares of common stock at a conversion price of $0.00 per share. To satisfy tax obligations, 21,892 shares of common stock were disposed of at $13.89 per share through tax withholding, rather than an open-market sale. Following these transactions, he directly owns 90,114 shares of common stock. The restricted stock units stem from a 194,600-unit grant made on August 13, 2024, vesting in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.
Avalo Therapeutics, Inc. Chief Financial Officer Christopher Ryan Sullivan reported routine equity compensation activity involving restricted stock units (RSUs). On March 28, 2026, 24,200 RSUs converted on a one-for-one basis into 24,200 shares of common stock at a stated price of $0.00 per share.
Of the resulting common shares, 8,241 were disposed of at $13.89 per share to satisfy tax obligations, leaving 33,297 shares of common stock held directly after the transactions. A prior grant of 72,600 RSUs from August 13, 2024 vests in three equal installments on March 28, 2025, 2026, and 2027, subject to continued service.
Avalo Therapeutics director Mitchell Chan exercised restricted stock units that vested into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a conversion price of $0.00 per share.
Following the transaction, Chan directly owned 6,333 shares of Avalo Therapeutics common stock. The restricted stock units convert into common stock on a one-for-one basis and are part of a 9,500-unit grant that vests in three equal annual installments starting March 28, 2025.
Avalo Therapeutics director Jonathan Goldman exercised restricted stock units into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of Avalo Therapeutics common stock at an exercise price of $0.00 per share. This reflects a derivative exercise, not an open-market purchase or sale.
According to prior grant terms, Goldman received 9,500 restricted stock units on August 13, 2024, vesting in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent on continued service.
Avalo Therapeutics, Inc. reported that two members of its board of directors, Dr. Jonathan Goldman and Mitchell Chan, have decided not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Both directors will continue serving on the board until that meeting.
The company stated that their decisions are not the result of any disagreement with Avalo on matters related to operations, policies, or practices. The board expressed its appreciation to Dr. Goldman and Mr. Chan for their service and contributions.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on IL-1β‑based treatments for immune‑mediated inflammatory diseases. Its lead antibody, abdakibart (AVTX‑009), is in a Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.
The company is prioritizing completion of this trial and planning potential Phase 3 studies and indication expansion while exploring strategic alternatives for several legacy programs. As of December 31, 2025, Avalo reported $98.3 million in cash, cash equivalents and short‑term investments and $12.9 million in current liabilities, and believes existing funds can support operations into 2028, though additional capital will likely be needed before Phase 3 or broader development.
Avalo Therapeutics reported 2025 results and highlighted progress on its lead drug abdakibart (AVTX-009). The company expects topline data from its Phase 2 LOTUS trial in hidradenitis suppurativa in the second quarter of 2026, a key milestone for its IL‑1β-based strategy.
Cash, cash equivalents and short-term investments were $98.3 million as of December 31, 2025, which Avalo expects will fund operations into 2028. Research and development expenses rose to $50.1 million and general and administrative expenses to $22.9 million, contributing to a net loss of $78.3 million for 2025.